Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million. What happened According to its SEC filing dated February 17, 2026, BVF fully liquidated its stake in Protagonist Therapeutics (NASDAQ:PTGX) , selling 2,560,916 shares. The quarter-end position value decreased by $170.12 million. What else to know BVF sold out of Protagonist Therapeutics. Top holdings after the filing: NASDAQ:KYMR: $428.17 million (14.4% of AUM) NASDAQ:RVMD: $267.37 million (9.0% of AUM) NASDAQ:MLTX: $260.32 million (8.8% of AUM) NASDAQ:GPCR: $241.97 million (8.1% of AUM) NASDAQ:OLMA: $132.40 million (4.5% of AUM) As of February 17, 2026, shares of Protagonist Therapeutics were priced at $82.46, up 120% over the past year and significantly outperforming the S&P 500's roughly 13% gain in the same period. Company overview Metric Value Market Capitalization $5.16
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics (PTGX) had its price target raised by The Goldman Sachs Group, Inc. from $65.00 to $95.00. They now have a "neutral" rating on the stock.MarketBeat
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera [Yahoo! Finance]Yahoo! Finance
- Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- 2/25/26 - Form 8-K
- PTGX's page on the SEC website